Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results

Curis (NASDAQ:CRIS) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06), MarketWatch Earnings reports. The company had revenue of $3.29 million during the quarter. During the same period in the prior year, the firm earned ($0.18) earnings per share.

NASDAQ:CRIS traded down $0.01 on Friday, reaching $0.74. The company’s stock had a trading volume of 2,280 shares, compared to its average volume of 163,167. Curis has a 1-year low of $0.65 and a 1-year high of $2.90. The firm has a market cap of $24.83 million, a PE ratio of -0.83 and a beta of 2.15. The business’s 50-day moving average price is $1.31 and its two-hundred day moving average price is $1.72.

Separately, ValuEngine upgraded shares of Curis from a “hold” rating to a “buy” rating in a report on Saturday, March 14th.

About Curis

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Featured Article: How does the Federal Reserve determine interest rates?

Earnings History for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.